Clinical Trial Update: A Study to Evaluate the Effect of KarXT on Urological Safety [Phase 4]

View source ↗

Summary

Phase 4 trial update examining the effect of KarXT on urological safety in people with schizophrenia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Schizophrenia | Phase 4 | Status: RECRUITING